123 related articles for article (PubMed ID: 17671153)
21. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
22. Motesanib and advanced NSCLC: experiences and expectations.
Raghav KP; Blumenschein GR
Expert Opin Investig Drugs; 2011 Jun; 20(6):859-69. PubMed ID: 21534718
[TBL] [Abstract][Full Text] [Related]
23. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
24. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
25. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
Gridelli C; Rossi A
Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
[TBL] [Abstract][Full Text] [Related]
26. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
Sandler A; Hirsh V; Reck M; von Pawel J; Akerley W; Johnson DH
Lung Cancer; 2012 Oct; 78(1):1-7. PubMed ID: 22877947
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
30. Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.
Lau SC; Rosa DD; Jayson G
Curr Opin Mol Ther; 2005 Oct; 7(5):493-501. PubMed ID: 16248285
[TBL] [Abstract][Full Text] [Related]
31. [Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors].
Rollino C; Beltrame G; Ferro M; Quattrocchio G; Tonda L; Quarello F
G Ital Nefrol; 2010; 27 Suppl 50():S70-4. PubMed ID: 20922699
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Park MS; Ravi V; Araujo DM
Curr Opin Oncol; 2010 Jul; 22(4):351-5. PubMed ID: 20485168
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies for non-small cell lung cancer: an evolving landscape.
Pal SK; Figlin RA; Reckamp K
Mol Cancer Ther; 2010 Jul; 9(7):1931-44. PubMed ID: 20571071
[TBL] [Abstract][Full Text] [Related]
34. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
35. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
36. VEGF family members regulate myocardial tubulogenesis and coronary artery formation in the embryo.
Tomanek RJ; Ishii Y; Holifield JS; Sjogren CL; Hansen HK; Mikawa T
Circ Res; 2006 Apr; 98(7):947-53. PubMed ID: 16527987
[TBL] [Abstract][Full Text] [Related]
37. Targeting vascular endothelial growth factor in lung cancer.
Hasani A; Leighl NB
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S484-6. PubMed ID: 21102250
[No Abstract] [Full Text] [Related]
38. Cutaneous side effects of inhibition of VEGF signal transduction.
Wozel G; Sticherling M; Schön MP
J Dtsch Dermatol Ges; 2010 Apr; 8(4):243-9. PubMed ID: 19832927
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer.
Spagnuolo A; Palazzolo G; Sementa C; Gridelli C
Expert Opin Pharmacother; 2020 Mar; 21(4):491-506. PubMed ID: 31957503
[No Abstract] [Full Text] [Related]
40. Molecular targets for retinal vascular diseases.
Campochiaro PA
J Cell Physiol; 2007 Mar; 210(3):575-81. PubMed ID: 17133346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
